Myriad Genetics 8-K
Executive pay
One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.
Filed 2026-11-09 16:01 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
One-time executive retention stock-option awards. On 11/06/2026, Myriad Genetics approved awards for its CFO, COO and chief scientific officer to support leadership continuity as it works to improve operational efficiency and financial performance.
Key Figures
- Options cover 121,379 shares for CFO Benjamin R. Wheeler, 146,933 for COO Mark S. Verratti and 92,632 for Chief Scientific Officer Dale Muzzey.
- The exercise price equals the common stock’s closing price on the grant date. Options vest and become exercisable on the third anniversary, subject to continued service, and have a 10-year term.
- After termination other than for death, disability or cause, vested options generally may remain exercisable for three months; termination for cause immediately ends the options, whether vested or not. The awards are also subject to each recipient’s applicable severance and change-in-control agreement.
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-09 23:37:31Z